Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. - Wikidata - awgldk - TriplyDB

Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome.

Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome.

http://www.wikidata.org/entity/Q36473553

about

RASopathies: unraveling mechanisms with animal models BRaf signaling principles unveiled by large-scale human mutation analysis with a rapid lentivirus-based gene replacement method.Aberrant neuronal activity-induced signaling and gene expression in a mouse model of RASopathy.Prioritizing the development of mouse models for childhood brain disorders Shp2 in forebrain neurons regulates synaptic plasticity, locomotion, and memory formation in mice Cardiomyopathies in Noonan syndrome and the other RASopathies.Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome.Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex Low-dose dasatinib rescues cardiac function in Noonan syndrome.Postnatal activation of TLR4 in astrocytes promotes excitatory synaptogenesis in hippocampal neurons.Combined effect of BCG vaccination and enriched environment promote neurogenesis and spatial cognition via a shift in meningeal macrophage M2 polarization.miR-181a involves in the hippocampus-dependent memory formation via targeting PRKAA1.Attention deficit hyperactivity disorder (ADHD) in phenotypically similar neurogenetic conditions: Turner syndrome and the RASopathies Perturbed proteostasis in autism spectrum disorders.Impaired synaptic plasticity in RASopathies: a mini-review.Modeling RASopathies with Genetically Modified Mouse Models.Increased Activity of Src Homology 2 Domain Containing Phosphotyrosine Phosphatase 2 (Shp2) Regulates Activity-dependent AMPA Receptor Trafficking.Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors.Synaptic plasticity through activation of GluA3-containing AMPA-receptors.HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models SPIN90 Modulates Long-Term Depression and Behavioral Flexibility in the Hippocampus TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response.Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study.Multiple repressive mechanisms in the hippocampus during memory formation.Src homology 2 domain-containing phosphotyrosine phosphatase 2 (Shp2) controls surface GluA1 protein in synaptic homeostasis.Increased Src Family Kinase Activity Disrupts Excitatory Synaptic Transmission and Impairs Remote Fear Memory in Forebrain Shp2-Deficient Mice.ERKquake in Noonan syndrome: one step closer to personalized medicine.The first international conference on SYNGAP1-related brain disorders: a stakeholder meeting of families, researchers, clinicians, and regulators.Atorvastatin enhances kainate-induced gamma oscillations in rat hippocampal slices.Species-conserved SYNGAP1 phenotypes associated with neurodevelopmental disorders.Neurodevelopment. "RASopathic" astrocytes constrain neural plasticity.Mek1Y130C mice recapitulate aspects of human cardio-facio-cutaneous syndrome.Comparisons of behavior and synaptic plasticity among three C57BL/6 substrains Social support rescues acute stress-induced cognitive impairments by modulating ERK1/2 phosphorylation in adolescent mice

P2860

Q26800379-0EC07C35-CD12-4D32-B2CE-8E7BDB296F4C Q30252647-1203BA9F-4C5B-4B6D-A19C-8DB824782820 Q30357327-D2626A60-F8F0-489F-AB74-99BC1BECF3CD Q30366940-87677897-ACFA-4706-8EA4-9F2D48860A6B Q30399984-7AB9DEFC-19F6-449C-AD31-3E559E1ABCD9 Q36057294-02646F34-8A12-47E3-9D5F-8AB2F70D9B38 Q36157128-9AE703C6-21EA-4502-ABDF-027AFFBD8545 Q36594223-2450338F-50B8-4D5B-8ACD-536A77A9A536 Q37469169-351452C2-74F2-4FB2-9E61-64BEC105DE43 Q37488326-AE60F6FA-FB7E-4C54-B927-81AE2E45B599 Q37635183-3E4BE1D1-07DC-40A1-BBF5-9D66C78CCA27 Q38641480-5D613817-33B7-487B-B509-888283A4E08F Q38659714-25A76F44-5A3E-4BA3-9C3A-009F6A3019D2 Q38882773-2548BF48-3636-4055-8DA5-8069225A630C Q38937954-D6AECD17-D091-4BEA-8643-3831FB87C1FC Q39031139-71FB2CA5-B85F-484F-A0DD-E5115797AA0E Q40650977-4BB99B35-650E-4BD1-8A97-3C856AC15CDB Q41075808-ACE3616C-D62D-4786-98EA-DCAC25CE6FFF Q41249331-CF837EC8-1513-4A7C-B1A6-D34DED02FAEE Q41578176-35F08B82-00AC-42B9-A422-E9CC717755B4 Q41722445-F89733B2-A206-4070-A3D8-7CFFB7E4A670 Q42132309-91A02A3A-2D78-4925-B4C0-5A89ADE28AE8 Q42363198-8AECCAFA-6EAE-4018-BEC5-1D6846219005 Q46655839-5F771417-AA0B-406B-B9FA-77535A6117A4 Q47417440-FE3C8A8B-BBC6-4A49-87F6-67075B6028AF Q47637189-CBD1008E-05A7-4102-8F4C-7F76AF44D01D Q47998759-E31048E4-FD37-4E90-88D6-88157724FDBA Q48262635-497C5090-0C18-4E31-879B-8D46CA71CBAA Q48451148-E150E932-DC29-46B7-B504-63FC19F5204C Q48506226-78B379E6-FC39-4103-9042-4A37859ECAA9 Q48659946-B805EB37-BAD2-4A37-BF80-B4A2C7571F9E Q52629859-18C63A56-A8AB-4203-B4B2-E14DE982C8B6 Q53514814-0CF33879-6BB1-4181-BC52-F62260478524 Q54974212-3991A4F0-BFCB-4A24-94AF-3AAED541BA46 Q58164561-AEC8440C-C5BB-4F2C-B32C-A6491C832470 Q58786981-29FB3F38-5E37-445D-B32B-890E12DD270A

P2860

Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome.

http://www.wikidata.org/entity/Q36473553

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Mechanism and treatment for le ...... use models of Noonan syndrome.

@ast

Mechanism and treatment for le ...... use models of Noonan syndrome.

@en

type

label

Mechanism and treatment for le ...... use models of Noonan syndrome.

@ast

Mechanism and treatment for le ...... use models of Noonan syndrome.

@en

prefLabel

Mechanism and treatment for le ...... use models of Noonan syndrome.

@ast

Mechanism and treatment for le ...... use models of Noonan syndrome.

@en

P1433

Q36473553-2CC71CFA-4242-4D04-95D4-A6F6AD5A41BE

P1476

Q36473553-C4B88B4F-8115-4189-B46D-6140C0ED5164

P2093

Q36473553-1055A9E5-085E-4F04-9CF1-006D23E098E3

Q36473553-11280A8C-7CBC-4FD6-AF93-7D1DE4CB9047

Q36473553-18B4565D-0F44-4E38-A761-521417E4AD03

Q36473553-6091725E-D1F0-4E82-AD68-BE68853B6017

Q36473553-618AA2D4-A41D-4751-AA1D-67CF53C2C40A

Q36473553-6BE92513-90D0-4805-B67A-055D088BBEC5

Q36473553-71CF38C3-5D3F-48B2-8B51-2913E0B9DBB9

Q36473553-7A989DF0-A6DE-4DFA-B836-96546F6C65CA

Q36473553-7C9C38DD-ACD3-4A9B-9C6F-2FE858365677

Q36473553-90EC8988-EB80-40B9-8E03-9A04160B9AC3

P2860

Q36473553-01DA7E78-83C1-4C5B-AF1C-A640A2EBF54A

Q36473553-07B22707-49EF-47E3-BFC3-F90C0F5B015A

Q36473553-0CEF9EFD-91E7-46D6-869F-24D3645714FA

Q36473553-10ADA53C-2562-4C70-B05C-8DAEBE5B75A9

Q36473553-2CAA5D21-7F66-42A1-A3F7-5C0B94AB758E

Q36473553-2D37A7BA-D090-4F9E-9E9A-C8C976105F57

Q36473553-331534D2-F465-4F48-92B0-D8EF3DF4929E

Q36473553-383C2074-E210-4CF3-BC66-76E05AD6F110

Q36473553-3DFBB621-4233-42EA-B69F-0B1724623780

Q36473553-461C8FB8-1B08-4F7C-A579-92F5BD2ABD43

P2888

Q36473553-A8E2D578-91ED-4892-92FA-0AEB76267782

P304

Q36473553-9A4ADAB2-71B7-4896-AD48-25890A9384B9

P31

Q36473553-E1A3DFBD-C9ED-45A5-AA44-71075C6ACBA9

P356

Q36473553-09FE2FAD-43EF-45C2-A267-FE08AD76D772

P407

Q36473553-A774BAAA-239A-45E9-9C5D-9BCA3A614A75

P433

Q36473553-FA0AC897-9CA3-4523-A30D-764EE1D16E6F

P478

Q36473553-394717A7-81D2-46EC-9731-FC8EC5629318

P50

Q36473553-0365311E-7C9A-4BC1-8EBB-B669870D7827

Q36473553-0D8141A4-24A7-4858-895C-2D5B7A9C0550

Q36473553-2D696202-3A9C-44B7-9A5A-138A922FE1E4

P577

Q36473553-87FE91E2-B08D-49B7-B23D-59064D7C4EDC

P5875

Q36473553-DF2922E1-0FA3-4488-B0A9-5D2B2F05F814

P698

Q36473553-5691F193-8FC6-4791-B2E7-AD96E41C7908

P932

Q36473553-D6E9D2D0-5CBE-47FC-841B-9663B8DDBCFF

P356

P1433

Nature Neuroscience

P1476

Mechanism and treatment for le ...... ouse models of Noonan syndrome

@en

P2093

Benjamin G Neel

http://www.w3.org/2001/XMLSchema#string

Bong-Kiun Kaang

http://www.w3.org/2001/XMLSchema#string

Christine I Nam

http://www.w3.org/2001/XMLSchema#string

Chuljung Kwak

http://www.w3.org/2001/XMLSchema#string

Dan Ehninger

http://www.w3.org/2001/XMLSchema#string

Delana Butz

http://www.w3.org/2001/XMLSchema#string

Hyong Kyu Kim

http://www.w3.org/2001/XMLSchema#string

Hyun-Hee Ryu

http://www.w3.org/2001/XMLSchema#string

J Balaji

http://www.w3.org/2001/XMLSchema#string

Jun-Young Oh

http://www.w3.org/2001/XMLSchema#string

P2860

Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation

The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1

Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation

Place navigation impaired in rats with hippocampal lesions

Ras and Rap signaling in synaptic plasticity and mental disorders.

Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome

P2888

P304

1736-1743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NN.3863

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Alcino J. Silva

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268154580

http://www.w3.org/2001/XMLSchema#string

P698

25383899

http://www.w3.org/2001/XMLSchema#string

P932

4716736

http://www.w3.org/2001/XMLSchema#string